Immunovaccine Inc.

Cell and Gene Therapy

Brooklyn ImmunoTherapeutics, Inc. | December 18, 2021

Brooklyn ImmunoTherapeutics, Inc. on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announces that Brooklyn has been added to the ICE Biotechnology Index following the December 20, 2021 reconstitution. “The continued recognition of Brooklyn among key biotechnology indices is encouraging and we continue to believe that our value proposition and approach to...

Anixa Biosciences | July 03, 2020

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Roche | May 13, 2020

KAPA HyperExome is a state-of-the-art whole exome research panel with improved performance over the on-market SeqCap portfolio, providing improved coverage and uniformity. The KAPA Target Enrichment portfolio empowers clinical researchers to process more sa...

Integral Molecular | June 12, 2020

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, t...